EyePoint Pharmaceuticals, Inc. EYPT Income Statement

Eyepoint pharmaceuticals, inc. (EYPT)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10
Revenues:
Total revenues
25,842	20,365	14,173	12,150	5,655	4,571	0	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaborative research and development
-	-	-	-	-	-	-	-	-	1,434	-	-	6,134	5,812	252	-	428	488	510	25,411	25,361	26,927	27,063	2,155	2,326	889	784	780	860	779	788	2,080	5,217	5,115	4,999	3,612	0	0	0
Royalty income
-	-	-	-	-	-	-	-	-	1,175	-	-	1,008	1,064	1,179	-	1,297	1,241	1,214	1,154	1,087	1,185	1,120	1,318	1,347	1,305	1,403	1,363	1,490	1,596	1,632	1,446	1,325	1,249	1,149	1,353	0	0	0
Total revenues
-	-	-	-	-	-	-	-	-	2,609	-	-	7,142	6,876	1,431	-	1,725	1,729	1,724	26,565	26,448	28,112	28,183	3,473	3,673	2,194	2,187	2,143	2,350	2,375	2,420	3,526	6,542	6,364	6,148	4,965	0	0	0
Operating expenses:
Cost of sales, excluding amortization of acquired intangible assets
0	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of sales, excluding amortization of acquired intangible assets
-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
16,424	15,368	15,415	18,164	18,974	18,502	18,592	16,178	15,626	15,625	14,521	14,880	14,771	14,521	15,077	14,381	13,475	13,740	12,786	12,088	11,196	10,126	9,853	9,573	9,587	8,905	7,986	7,005	6,095	6,016	6,433	7,039	7,480	7,709	7,251	6,864	0	0	0
Sales and marketing
30,586	29,772	26,901	22,769	16,997	0	0	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
17,689	17,939	18,530	18,326	17,731	15,402	13,134	11,545	9,949	10,094	10,522	11,235	11,267	11,187	10,330	9,013	8,768	8,463	8,290	8,056	7,645	7,550	7,391	7,468	7,621	7,413	7,360	7,169	6,615	6,634	6,427	6,868	7,441	7,446	7,996	8,104	0	0	0
Amortization of acquired intangible assets
2,460	2,460	1,845	1,230	615	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of acquired intangible assets
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-
Impairment of intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-
Total operating expenses
70,496	68,226	64,054	61,525	54,647	43,590	36,884	29,235	25,575	25,719	25,043	26,115	26,038	25,708	25,407	23,394	22,243	22,203	21,076	20,144	18,839	17,670	17,166	16,963	17,132	16,246	15,346	14,174	12,710	12,650	27,690	28,737	29,751	29,985	15,247	14,968	0	0	0
Loss from operations
-44,654	-47,861	-49,881	-49,375	-48,992	-39,019	-33,822	-26,274	-22,628	-23,110	-17,396	-18,576	-18,896	-18,832	-23,976	-21,774	-20,518	-20,474	-19,352	6,421	7,609	10,442	11,017	-13,490	-13,459	-14,052	-13,159	-12,031	-10,360	-10,275	-25,270	-25,211	-23,209	-23,621	-9,099	-10,003	0	0	0
Other income (expense):
Change in fair value of derivatives
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	170	180	514	844	1,140	0	0	0
Interest income, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	7	10	16	22	29	36	38	41	38	33	30	0	0	0
Interest and other income, net
865	1,054	930	876	637	419	207	101	94	89	90	91	102	103	86	72	47	36	29	22	0	0	0	-	-	-	-	-2	-2	-1	0	-1	-3	-4	-7	-13	0	0	0
Interest expense
6,940	6,176	5,216	4,261	3,382	0	0	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on extinguishment of debt
0	-3,810	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liability
-	-	-	-	-	-45,164	0	0	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other expense, net
-6,075	-8,932	-8,096	-26,081	-49,394	-47,107	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	14	20	28	164	207	218	548	870	1,157	0	0	0
Loss before income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-21,702	-20,471	-20,438	-19,323	6,443	7,627	10,451	11,024	-13,485	-13,454	-14,045	-13,150	-12,017	-10,340	-10,247	-25,106	-25,004	-22,991	-23,073	-8,229	-8,846	0	0	0
Income tax benefit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-155	-165	-175	-171	96	101	114	126	-130	-119	-103	-114	-117	-235	-250	-257	-169	-168	-251	-172	-218	0	0	0
Net loss
-50,729	-56,793	-57,977	-75,456	-98,386	-86,126	-80,314	-53,171	-24,859	-23,021	-17,306	-18,485	-18,756	-18,657	-23,776	-21,547	-20,306	-20,263	-19,152	6,347	7,526	10,337	10,898	-13,355	-13,335	-13,942	-13,036	-11,900	-10,215	-10,107	-24,959	-24,835	-22,713	-22,712	-7,947	-8,628	0	0	0
Net loss per share:
Net loss per share - basic and diluted
-0.11	-0.08	-0.15	-0.11	-0.20	-0.09	-0.44	-0.62	-0.15	-0.13	-0.15	-0.16	-0.15	0.00	-0.21	-0.18	-0.15	-0.18	-0.17	-	-	-	-	-	-	-	-	-	-0.12	-0.11	-0.11	-0.10	-0.13	-0.84	-0.12	0.01	-0.13	-0.15	-0.17
Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.17	-0.17	-0.14	0.70	-0.14	-0.08	-0.13	-0.14	-	-	-	-	-	-	-	-	-	-	-	-
Diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.15	-0.17	-0.14	0.67	-0.14	-0.08	-0.13	-0.14	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average common shares outstanding:
Weighted average shares outstanding - basic and diluted
115,530	108,600	106,938	106,238	95,452	94,944	75,170	55,387	45,644	44,530	39,430	38,658	34,366	34,177	34,175	63,487	33,538	29,437	29	-	-	-	-	-	-	-	-	-	23,297	23,297	22,294	20,801	20,803	20,803	20,757	20,717	20,177	18,531	18,531
Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	29,410	29,412	29,366	29,323	29,231	27,672	26,952	25,917	-	-	-	-	-	-	-	-	-	-	-	-
Diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32,792	29,412	29,366	30,765	29,231	27,672	26,952	25,917	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-50,729	-56,793	-57,977	-75,456	-98,386	-86,126	-80,314	-53,171	-24,859	-23,021	-17,306	-18,485	-18,756	-18,657	-23,776	-21,547	-20,306	-20,263	-19,152	6,347	7,526	10,337	10,898	-13,355	-13,335	-13,942	-13,036	-11,900	-10,215	-10,107	-24,959	-24,835	-22,713	-22,712	-7,947	-8,628	0	0	0
Other comprehensive income (loss):
Foreign currency translation adjustments
1	1	2	2	2	3	1	5	13	12	-2	-21	-58	-79	-83	-96	-22	-46	-73	-95	-117	-67	9	124	102	10	-23	-29	-74	78	-70	-492	0	0	0	-	-	-	-
Net unrealized gain on marketable securities
-	-	-	-	-	-	-	-	-	1	-	2	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net unrealized gain on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	-3	1	-	-5	0	0	-	0	-	-	7	-1	3	15	5	0	0	0	-	-	-	-
Other comprehensive income (loss)
-	-	-	-	-	-	-	5	13	13	-1	-19	-58	-71	-81	-93	-17	-49	-72	-99	-120	-72	6	124	105	14	-24	-22	-75	81	-55	-487	0	0	0	-	-	-	-
Comprehensive loss
-50,728	-56,792	-57,975	-75,454	-98,384	-86,123	-80,313	-53,166	-24,846	-23,008	-17,307	-18,504	-18,814	-18,728	-23,857	-21,640	-20,323	-20,312	-19,224	6,248	7,406	10,265	10,904	-13,231	-13,230	-13,928	-13,060	-11,922	-10,290	-10,026	-25,014	-25,322	0	0	0	-	-	-	-
Product [Member]
Total revenues
20,284	16,824	8,941	7,932	1,227	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License and Collaboration Agreement [Member]
Total revenues
0	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaborative Research and Development [Member]
Total revenues
-	-	-	0	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalty Income [Member]
Total revenues
2,242	2,180	2,281	2,265	2,262	1,946	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-